Global Acromegaly and Gigantism Drugs Market 2018-2022

◆상품코드 : IRTNTR20504
◆발행일 : 2018년 2월
◆페이지수 : 100
◆보고서 형식 : 一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど) / 영문
◆납품 방식 : Email
◆조사대상 지역 : 글로벌
◆산업분야 : 미분류
◆발행회사(조사회사) : Technavio
◆판매회사 : H&I글로벌리서치(주)
◆판매가격 옵션
Single User¥ -> 환산 ₩원화 가격은 문의주세요.견적의뢰/구매/질문FORM
Five User¥ -> 환산 ₩원화 가격은 문의주세요.견적의뢰/구매/질문FORM
Enterprise License¥ -> 환산 ₩원화 가격은 문의주세요.견적의뢰/구매/질문FORM
※지불하실 금액은 상기금액이며, 세금 및 배송료는 없습니다.
※지불은 선불결제 방식이며, 신용카드결제 또는 계좌입금(국내/해외)이 선택가능합니다.
※구매의사를 FORM기입 또는 E메일로 연락주시면 담당자가 회신 드리겠습니다.
※배송은 입금 확인 후, E메일로 납품드리며, 일반적으로 당일~2일정도 소요됩니다.
※가격옵션 설명 : (Single User : 귀사내에서 1명만 사용가능 / Five User, Multi User : 귀사내에서 5명까지 사용가능 / Site License, Corporate License : 동일국내에서 인원제한없이 사용가능 / Global Site License, Enterprise License : 지역상관없이 인원제한없이 사용/공유 가능한 라이센스). 자세한 설명은 이용안내 페이지를 참고하세요.


[조사보고서 개요]

About Acromegaly and Gigantism Drugs
The acromegaly and gigantism are GH-related diseases. Acromegaly disease occurs in adults while gigantism occurs in children.

Technavio’s analysts forecast the global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global acromegaly and gigantism drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of acromegaly and gigantism drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Ipsen
• Novartis
• Pfizer

[Market driver]
• Strong pipeline
• For a full, detailed list, view our report

[Market challenge]
• Difficulty in diagnosis
• For a full, detailed list, view our report

[Market trend]
• Growing popularity of drugs over surgeries
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

[조사보고서 목차]

Table of Contents
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
• Market outline

PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY DRUG CLASS
• Segmentation by drug class
• Comparison by drug class
• Somatostatin analogs – Market size and forecast 2017-2022
• GH receptor antagonists – Market size and forecast 2017-2022
• Dopamine agonists – Market size and forecast 2017-2022
• Recombinant human IGF-1 – Market size and forecast 2017-2022
• Market opportunity by product

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Americas – Market size and forecast 2017-2022
• EMEA – Market size and forecast 2017-2022
• APAC – Market size and forecast 2017-2022
• Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 14: MARKET TRENDS
• Growing popularity of drugs over surgeries
• Focus on long-acting novel formulations

PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Ipsen
• Novartis
• Pfizer

PART 17: APPENDIX
• List of abbreviations

[List of Exhibits] Exhibit 01: Parent market
Exhibit 02: Global acromegaly and gigantism drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global acromegaly and gigantism drugs market 2017-2022 ($ mn)
Exhibit 09: Global acromegaly and gigantism drugs market: Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials for global acromegaly and gigantism drugs market
Exhibit 20: Segmentation of global acromegaly and gigantism drugs market by drug class 2017-2022 (%)
Exhibit 21: Comparison by drug class
Exhibit 22: Somatostatin analogs – Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Somatostatin analogs – YoY growth 2018-2022 (%)
Exhibit 24: GH receptor antagonists – Market size and forecast 2017-2022 ($ mn)
Exhibit 25: GH receptor antagonists – YoY growth 2018-2022 (%)
Exhibit 26: Dopamine agonists – Market size and forecast 2017-2022 ($ mn)
Exhibit 27: Dopamine agonists – YoY growth 2018-2022 (%)
Exhibit 28: Recombinant human IGF-1 – Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Recombinant human IGF-1 – YoY growth 2018-2022 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Segmentation of global acromegaly and gigantism drugs market by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas – Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas – YoY growth 2018-2022 (%)
Exhibit 36: Top three countries in Americas
Exhibit 37: EMEA – Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA – YoY growth 2018-2022 (%)
Exhibit 39: Top three countries in EMEA
Exhibit 40: APAC – Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC – YoY growth 2018-2022 (%)
Exhibit 42: Top three countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Percentage increase in GDI of India, China, and US for 2011-2016
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Ipsen – Vendor overview
Exhibit 51: Ipsen – Business segments
Exhibit 52: Ipsen – Organizational developments
Exhibit 53: Ipsen – Geographic focus
Exhibit 54: Ipsen – Segment focus
Exhibit 55: Ipsen – Key offerings
Exhibit 56: Ipsen– Key customers
Exhibit 57: Novartis – Vendor overview
Exhibit 58: Novartis – Business segments
Exhibit 59: Novartis – Organizational developments
Exhibit 60: Novartis – Geographic focus
Exhibit 61: Novartis – Segment focus
Exhibit 62: Novartis – Key offerings
Exhibit 63: Pfizer – Vendor overview
Exhibit 64: Pfizer – Business segments
Exhibit 65: Pfizer – Organizational developments
Exhibit 66: Pfizer – Geographic focus
Exhibit 67: Pfizer – Segment focus
Exhibit 68: Pfizer – Key offerings
Exhibit 69: Pfizer – Key customers



[조사보고서에 언급된 기업]
PDF

[보고서에 포함된 내용]
세계시장규모, 세그멘트별 시장규모, 시장동향, 시장예측, 관련 기업정보 등

[면책사항]
http://www.globalresearch.kr/disclaimer

★조사보고서 [Global Acromegaly and Gigantism Drugs Market 2018-2022]에 관해서 E메일 문의 연락
◆H&I글로벌리서치의 고객기업(예)◆